CARLSBAD, Calif. — A sustained-release intravitreal hydrogel implant containing axitinib demonstrated durable results in patients with neovascular age-related macular degeneration, according to phase 1 study results.
The results, presented at the Women in Ophthalmology Summer Symposium, showed patients achieved stable central subfield thickness (CSFT) and best corrected visual acuity for up to 52 weeks.
Tyrosine kinase inhibitors such as axitinib may offer a broader antiangiogenic profile for the treatment of neovascular AMD compared with current anti-VEGF therapies, which require